Physician

Afzal H Khan, MD

According to 2025 Medicare claims, Afzal Khan, MD (NPI: 1942267190) practices hematology/oncology in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. This provider's primary affiliated billing organization is AFZAL H KHAN MD PA (NPI: 1740538792; TIN: 650524728) and primary practice location at 33169-5521.

Khan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 306 traditional Medicare patients, billed 3,046 HCPCS/CPT codes, and received $197,236 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 181 prescription claims across 26 beneficiaries totaling $1,211,977 in drug costs, led by Imbruvica (Ibrutinib). 2023 DME data shows 12 claims. Open Payments data shows 9 records totaling $193. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $350,435 and ending at $197,236. Concurrently, Part D prescription costs have fallen sharply in recent years, from $1,215,633 to $1,211,977. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	426	6,882	$350,435
2016	376	4,036	$284,208
2017	338	8,635	$231,192
2018	348	5,271	$271,073
2019	406	6,613	$300,072
2020	423	6,620	$416,043
2021	341	4,822	$294,764
2022	292	4,219	$298,746
2023	365	4,529	$357,922
2024	306	3,046	$197,236

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	138	949	$1,215,633
2016	158	1,183	$2,446,354
2017	161	1,167	$2,888,518
2018	180	1,155	$3,706,558
2019	159	907	$4,154,638
2020	76	435	$2,214,245
2021	51	341	$2,332,724
2022	49	292	$1,954,178
2023	30	168	$1,249,876
2024	26	181	$1,211,977

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	22	$921
2021	N/R	N/R	N/R
2022	N/R	12	$2,224
2023	N/R	12	$2,399
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	55	62	$142
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	213	250	$110
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	23	109	$97
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	253	1,614	$65
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	139	946	$42

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	39	1,092	$673,232
Brukinsa	Zanubrutinib	12	360	$181,720

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$193	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Afzal H. Khan, MD?

Tedicare shows public-source Medicare data for Afzal H. Khan, MD (NPI 1942267190), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Afzal H. Khan, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Afzal H. Khan, MD?

Afzal H. Khan, MD is linked to AFZAL H KHAN MD PA (billing NPI 1740538792) in the available physician profile data.

Does Afzal H. Khan, MD have Open Payments data?

Afzal H. Khan, MD has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.